B
Bullisch
Bullisch · 25%ONCO
$4.05
Szenariopreis
$0.598
+0.155 (+25.98%)Zum Schluss
Loading chart…
- Hoch
- 0.678
- Eröffnung
- 0.508
- Volumengewichteter Durchschnittskurs
- 0.59
- Volumen
- 45.22M
- Marktkap.
- —
- Tief
- 0.481
- Umsatz
- 26.48M
- EV/EBITDA, TTM
- 0.00
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
KI-Analyse of Onconetix Inc (ONCO)
VerkaufenOnconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Onconetix Inc (ONCO) beträgt 0.00, verglichen mit dem 5-Jahres-Durchschnitt von -2.37.
Alphio-AI-Kursszenarien für ONCO
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
8.510-26NewsfilterOnconetix Approves 1-for-10 Reverse Stock Split
8.509-15NASDAQ.COMOnconetix Provides Strategic Financing to Realbotix Ahead of Acquisition
8.509-03NASDAQ.COMOnconetix Acquires Realbotix, Launches Robot Pilot Program
9.508-27Yahoo FinanceOncopeptides Reports Strong Q2 2026 Earnings Growth
8.508-06GlobenewswireOnconetix Advances Acquisition of Realbotix Amid Humanoid Robotics Adoption
ONCO FAQ – beantwortet von Alphio AI
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Onconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.